FDA Tries Again To Ban Natural Pain Herb

FDA Tries Again To Ban Kratom

Kratom plant

Last year, I wrote about the Food and Drug Administration’s campaign to ban the Asian herb Kratom, a non-opiate option for those with chronic pain, anxiety, and drug dependency issues.

As someone interested in medical strategies for disaster or remote settings, I was considering the herb as an option in circumstances when modern medicine isn’t available. The FDA, however, set a date for late 2016 to rule Kratom a Schedule I drug (the same category as heroin) and eliminate its access to the average citizen.

Then an extraordinary thing happened: A public outcry from tens of thousands of citizens that also included dozens of members of Congress. In response to the pressure, the proposed ban was cancelled. Now, a persistent FDA is once again pushing to prevent the sale and use of Kratom in the U.S.

Kratom (scientific name Mitragyna speciosa)

This post was originally published on this site
Comments are closed.